Watchlist for February 13, 2008

This morning’s retail sales report has given a boost to the futures. The indices are set to open near yesterday’s highs. Let’s see if the bulls can push through levels today.

On Today’s Calendar:

• 10:00 — Business Inventories
• 10:00 — Crude Inventories

More Calendars: U.S. Earnings | Conf. Calls | Surprises | IPO | Economic

Potential swing trades:

See one of the recent ‘Chart Reading‘ posts for some potential swing candidates. Also be sure to check my typical swing trade entry & exit rules.

Potential day trades:

(From Briefing.com)

Gapping Down

In reaction to weak earnings/guidance: NILE -25.7% (downgraded to Hold at Citigroup), ATAC -10.3%, DF -9.4%, CSCD -9.0%, OSUR -8.5%, MOSY -5.6%, ANAD -5.4%, DAKT -5.0%, HCSG -5.0%, WYNN -3.2%, DE -1.1%, MT -1.0%… Other news: ABB -6.2% (CEO Kindle quits over `irreconcilable differences’ – Bloomberg.com), TS -2.3% (showing weakness after trading lower overseas)… Analyst downgrades: DKS -1.7% (downgraded to Neutral at Susquenna), ACI -1.7% (downgraded to Neutral at Calyon), MS -1.2% (downgraded to Perform at Oppenheimer).

Gapping Up

In reaction to strong earnings/guidance: FSLR +21.3%, CPSS +13.3%, XNN +13.2%, BWLD +12.2%, ATAR +11.9%, XPRT +11.0%, VOLC +8.9%, WSPI +8.8%, RICK +5.6%, OCNF +4.7%, CEPH +4.3% (upgraded to Strong Buy at Broadpoint), PFCB +3.7%, BOBE +3.6%, JNY +3.6%, GXDX +1.6%, ABD +1.5%, NTWK +1.3%, KO +1.1%, VG +1.0%… Other news: BRKS +4.6% (Rio Tinto posts solid results, says BHP must boost offer ‘considerably’ – WSJ), TASR +2.8% (announces 3 more product liability lawsuit dismissals), DNA +2.2% (announces Avado study of Avastin Plus docetaxel chemotherapy showed improved progression-free survival in patients with advanced breast cancer), CECO +1.7% (announces co-wide restructuring as part of long term growth strategy), PNCL +1.5% (releases January performance data for Colgan Air and Pinnacle Airlines), INTV +1.3% (secures multi-million dollar expansion contract with major U.S. telecommunications company)… Analyst upgrades: DYN +3.3% (upgraded to Buy at Citigroup), BCSI +2.5% (initiated with a Buy at Brean Murray), SGP +1.9% (upgraded to Buy at BofA), VRX +1.7% (upgraded to Peer Perform at Bear Sterns), HL +1.3% (upgraded to Outperform from Market Perform at BMO Capital).

Disclaimer & How I use this list